TH
Tharimmune, Inc.
THAR · NASDAQ
$3.54 +6.63% (+$0.22)
Piotroski F-Score Weak
2/9Valuation
-
N/A EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
37 /100
Moderate Beta 1.45x
EPS volatility N/A
Profitable years N/A
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre THAR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mark Wendland
Employees
2
Headquarters
Bridgewater